Key result
Rare cardiac chloromas in AML require multimodal imaging and systemic chemotherapy despite poor prognosis.
Why the study?
Cardiac chloromas are rare extramedullary tumors associated with acute myelogenous leukemia whose diagnosis is challenging due to rarity and variable clinical presentation.
Cardiac chloromas are rare, aggressive tumors associated with acute myeloid leukemia that require multimodality imaging for detection and systemic chemotherapy for management.
May warrant consideration in AML with cardiac symptoms; leaves open prospective validation of multimodal strategies.
Cardiac chloromas are rare extramedullary tumors associated with acute myelogenous leukemia that can infiltrate cardiac tissues, disrupt normal function, and contribute to heart failure. Their diagnosis is challenging due to their rarity and variable clinical presentation. Imaging techniques such as echocardiography, MRI, CT, and PET/CT are necessary for detecting these masses and assessing their extent. Histopathologic analysis confirms the diagnosis by identifying leukemic markers within the tumor. Systemic chemotherapy remains the primary treatment, but prognosis remains poor due to the aggressive nature of acute myeloid leukemia and the complexity of managing cardiac involvement.
No takes yet. Share an insight, caveat, or question.
Burstein et al. (2026) conducted a review in Cardiac chloroma. Cardiac chloromas are rare extramedullary tumors in acute myeloid leukemia that require multimodal imaging for diagnosis and systemic chemotherapy, though prognosis remains poor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: